Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Eoganachton Oct 29, 2023 3:42pm
397 Views
Post# 35706460

Another research paper on Ruthenium based PDCs

Another research paper on Ruthenium based PDCsBODIPY-ruthenium(II) polypyridyl complexes: Synthesis, computational, spectroscopic, electrochemical, and singlet oxygen studies

Jeremy Erb, Darcy Setter, Jake Swavey, Frederick Willits, Shawn Swavey
Department of Chemistry, University of Dayton, 300 College Park, Dayton, OH 45469, United States

Received 18 July 2023, Revised 18 September 2023, Accepted 22 October 2023, Available online 29 October 2023.
 
"...A substantial quantity of research related to developing next generation photosensitizers has resulted in a better understanding of the mechanism of PDT and thus new photosensitizer scaffolds [3], [4], [5]. With their synthetic versatility and exciting photochemical properties Ruthenium(II) polypyridyl complexes occupy a significant proportion of research in the development of new PDT agents [6], [7], [8], [9], [10]. Much of the recent research has focused on extending the aromaticity of the pyridyl ligands to allow for excitation of the Ru-PS within the PDT window (600–850nm) [11], [12], [13], [14], [15], [16]. Currently, however; the only ruthenium-based PDT complex under clinical human trials is TLD1433 which is being evaluated for bladder cancer [17]...."
 
<< Previous
Bullboard Posts
Next >>